Sarepta Therapeutics Reports Q1 2026 Revenue of $730.8M, Net Income of $331M

Sarepta Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $730.8 million, a slight decrease of 2% from $744.9 million in the same period last year. The decline was primarily attributed to a significant drop in product sales, which fell by 46% to $330.5 million, down from $611.5 million. This decrease was largely driven by reduced sales of its gene therapy product, ELEVIDYS, which saw a 73% decline in revenue to $102.0 million, reflecting changes in demand following safety events and subsequent label updates. In contrast, collaboration and other revenues surged by 200% to $400.3 million, bolstered by a $365 million collaboration revenue recognized from a partnership with Roche.

The company’s operating expenses also saw a substantial reduction, with total costs and expenses decreasing by 64% to $372.4 million, compared to $1.0 billion in the prior year. This reduction was driven by a significant 80% decrease in research and development expenses, which fell to $154.0 million from $773.4 million, largely due to the absence of large upfront payments related to collaboration agreements that were recorded in the previous year. Selling, general, and administrative expenses also decreased by 18% to $109.0 million, reflecting cost-cutting measures implemented as part of a strategic restructuring plan.

Sarepta's net income for the quarter was $331.0 million, a notable turnaround from a net loss of $447.5 million in the same quarter of 2025. This improvement was attributed to the combination of increased collaboration revenues and reduced operating expenses. The company reported earnings per share of $3.15, compared to a loss of $4.60 per share in the prior year. The weighted average number of shares outstanding increased to 104.99 million from 97.36 million, contributing to the positive earnings per share figure.

Operationally, Sarepta's cash and cash equivalents decreased to $464.5 million as of March 31, 2026, down from $801.3 million at the end of 2025. The company also reported a significant reduction in current liabilities, which fell by 54% to $499.2 million, primarily due to a decrease in deferred revenue. The total working capital increased by 26% to $1.81 billion, indicating improved liquidity. The company believes that its current cash position, along with future cash inflows from operations and access to its revolving credit facility, will be sufficient to fund its operational plans for at least the next twelve months.

Looking ahead, Sarepta plans to continue its focus on advancing its pipeline of RNA-targeted therapeutics and gene therapies for rare diseases. The company is also working to address regulatory concerns related to ELEVIDYS and is conducting various clinical trials to verify the clinical benefits of its products. The strategic restructuring plan announced in July 2025 aims to enhance financial flexibility and align the company’s cost structure with its strategic priorities, which may include further collaborations and potential product launches in the future.